Drugs with Biggest Price Increases (2026)

The largest year-over-year increase is +312.4%. These 50 drugs have seen the most dramatic cost increases in Medicare Part D spending.

#	Drug	Condition	YoY Change	Cost/Claim	Medicare Spending	Generic?
1	Mounjaro Tirzepatide	Diabetes	+312.4%	$673.00	$2.5B	No
2	Leqvio Inclisiran	High Cholesterol	+186.4%	$1,391.00	$345.0M	Yes
3	Wegovy Semaglutide (weight)	Obesity	+185.6%	$820.00	$2.3B	Yes
4	Vabysmo Faricimab	Eye Diseases	+156.3%	$663.00	$1.2B	Yes
5	Enhertu Fam-Trastuzumab Deruxtecan	Cancer	+125.4%	$16,930.00	$1.5B	Yes
6	Tezspire Tezepelumab	Asthma/COPD	+124.6%	$3,081.00	$456.0M	Yes
7	Kerendia Finerenone	Kidney Disease	+124.6%	$399.00	$345.0M	Yes
8	Opzelura Ruxolitinib (topical)	Dermatology	+124.6%	$375.00	$234.0M	Yes
9	Brukinsa Zanubrutinib	Cancer	+86.5%	$9,952.00	$1.2B	Yes
10	Cabenuva Cabotegravir/Rilpivirine	HIV	+86.4%	$6,593.00	$567.0M	Yes
11	Opdualag Nivolumab/Relatlimab	Cancer	+86.4%	$13,500.00	$567.0M	Yes
12	Qulipta Atogepant	Migraine	+86.4%	$528.00	$456.0M	Yes
13	Quviviq Daridorexant	Sleep Disorders	+86.4%	$271.00	$234.0M	Yes
14	Padcev Enfortumab Vedotin	Cancer	+82.3%	$14,515.00	$987.0M	Yes
15	Ozempic Semaglutide	Diabetes	+72.5%	$685.00	$5.0B	No
16	Kesimpta Ofatumumab	Multiple Sclerosis	+68.4%	$8,425.00	$1.6B	Yes
17	Trodelvy Sacituzumab Govitecan	Cancer	+68.4%	$15,643.00	$876.0M	Yes
18	Nurtec ODT Rimegepant	Migraine	+68.4%	$353.00	$876.0M	Yes
19	Gemtesa Vibegron	Prostate/Urology	+68.4%	$278.00	$345.0M	Yes
20	Lybalvi Olanzapine/Samidorphan	Mental Health	+68.4%	$375.00	$234.0M	Yes
21	Saphnelo Anifrolumab	Autoimmune Diseases	+68.4%	$5,563.00	$178.0M	Yes
22	Xcopri Cenobamate	Seizure/Epilepsy	+56.4%	$553.00	$345.0M	Yes
23	Qelbree Viloxazine	ADHD	+56.4%	$271.00	$234.0M	Yes
24	Skytrofa Lonapegsomatropin	Growth Disorders	+56.4%	$3,441.00	$234.0M	Yes
25	Nexlizet Bempedoic Acid/Ezetimibe	High Cholesterol	+56.4%	$285.00	$178.0M	Yes
26	Rinvoq Upadacitinib	Autoimmune Diseases	+56.3%	$3,498.00	$2.3B	No
27	Retevmo Selpercatinib	Cancer	+56.3%	$14,375.00	$345.0M	Yes
28	Verquvo Vericiguat	Heart Failure	+56.3%	$511.00	$178.0M	Yes
29	Breztri Aerosphere Budesonide/Glycopyrrolate/Formoterol	Asthma/COPD	+48.3%	$305.00	$756.0M	No
30	Spravato Esketamine	Depression/Anxiety	+45.6%	$1,839.00	$456.0M	Yes
31	Nubeqa Darolutamide	Cancer	+45.3%	$7,910.00	$1.2B	Yes
32	Skyrizi Risankizumab	Autoimmune Diseases	+42.8%	$4,475.00	$2.3B	No
33	Evrysdi Risdiplam	Rare Diseases	+42.6%	$31,500.00	$567.0M	Yes
34	Dayvigo Lemborexant	Sleep Disorders	+42.6%	$185.00	$345.0M	Yes
35	Lorbrena Lorlatinib	Cancer	+42.5%	$14,250.00	$456.0M	Yes
36	Reblozyl Luspatercept	Anemia	+42.4%	$6,593.00	$567.0M	Yes
37	Narcan Naloxone Nasal Spray	Opioid Dependence	+42.4%	$144.00	$178.0M	Yes
38	Sogroya Somapacitan	Growth Disorders	+42.4%	$2,070.00	$178.0M	Yes
39	Adbry Tralokinumab	Dermatology	+42.4%	$718.00	$178.0M	Yes
40	Caplyta Lumateperone	Mental Health	+42.3%	$457.00	$567.0M	Yes
41	Semglee Insulin Glargine-yfgn	Diabetes	+42.3%	$139.00	$345.0M	Yes
42	Nexletol Bempedoic Acid	High Cholesterol	+42.3%	$271.00	$234.0M	Yes
43	Lupkynis Voclosporin	Autoimmune Diseases	+42.3%	$4,875.00	$234.0M	Yes
44	Rybelsus Semaglutide (oral)	Diabetes	+38.7%	$428.00	$1.8B	Yes
45	Libtayo Cemiplimab	Cancer	+35.6%	$14,125.00	$678.0M	Yes
46	Dupixent Dupilumab	Autoimmune Diseases	+35.2%	$2,819.00	$4.4B	No
47	Calquence Acalabrutinib	Cancer	+34.2%	$10,105.00	$2.9B	Yes
48	Dovato Dolutegravir/Lamivudine	HIV	+32.6%	$2,910.00	$1.2B	Yes
49	Ultomiris Ravulizumab	Blood Disorders	+32.4%	$65,292.00	$1.6B	Yes
50	Ubrelvy Ubrogepant	Migraine	+32.4%	$305.00	$567.0M	Yes

Frequently Asked Questions

Price increases stem from patent protection (no competition), limited generic alternatives, rebate structures with pharmacy benefit managers, annual manufacturer price hikes, and increasing demand. Brand-name drugs without generic competition see the steepest increases.

Check the "Generic?" column. If a generic is available, ask your doctor about switching. Also explore manufacturer patient assistance programs, GoodRx coupons, or Mark Cuban's Cost Plus Drugs for lower prices.

Year-over-year change compares the current year's average cost per claim to the prior year's average cost per claim under Medicare Part D, expressed as a percentage change.

Cheapest Alternatives →